# Third Arc Bio

**Source:** https://geo.sig.ai/brands/third-arc-bio  
**Vertical:** BioTech  
**Subcategory:** Multifunctional Antibodies (T Cell Engagers)  
**Tier:** Emerging  
**Website:** thirdarcbio.com  
**Last Updated:** 2026-04-14

## Summary

Raised $52M Series A extension (Feb 2026) from a16z as new investor — total $217M. ARC101 (bispecific T cell engager, CLDN6+) in Phase 1 solid tumors. Platform spans oncology and autoimmune.

## Company Overview

Third Arc Bio raised a $52 million Series A extension in February 2026 with Andreessen Horowitz as a new investor, building on its prior $165 million Series A to reach $217 million in total financing. The company develops multifunctional antibodies — protein therapeutics that combine multiple mechanisms of action in a single molecule — with its lead program ARC101 being a bispecific T cell engager targeting CLDN6 in solid tumors, currently in Phase 1 clinical trials.

Bispecific T cell engagers (BiTEs) work by simultaneously binding a cancer-specific antigen on tumor cells and CD3 on T cells, bringing T cells into direct contact with cancer cells to trigger targeted tumor destruction. This approach has validated efficacy in hematologic cancers (blinatumomab, FDA-approved), but extending it to solid tumors requires addressing the immunosuppressive tumor microenvironment that prevents T cells from functioning effectively in solid cancer contexts. Third Arc's multifunctional antibody architecture addresses this by incorporating additional mechanisms beyond simple T cell engagement.

Andreessen Horowitz's decision to enter Third Arc as a new investor in the extension round — rather than waiting for the company's Series B — reflects strong conviction in the program's Phase 1 safety and early efficacy data, and positions a16z Bio at the earliest point in Third Arc's anticipated value creation curve.

## Frequently Asked Questions

### What does Third Arc Bio do?
Multifunctional antibodies combining T cell engagement with additional mechanisms — ARC101 bispecific T cell engager (CLDN6+) in Phase 1 solid tumor trials. Platform spans oncology and autoimmune.

### How much has Third Arc raised?
$217M total ($165M Series A + $52M extension with a16z as new investor, February 2026).

### What is a bispecific T cell engager?
Antibody that simultaneously binds a tumor antigen and T cells' CD3 receptor — bringing T cells into direct contact with cancer cells for targeted destruction. ARC101 applies this approach to solid tumors.

### Why did a16z enter as new investor in the extension?
Rather than waiting for Series B, a16z entered at the extension stage — reflecting strong conviction in Phase 1 safety/efficacy data and desire to capture value at the earliest stage.

### What makes Third Arc Bio's T cell engager platform differentiated?
Third Arc Bio develops multifunctional antibodies that simultaneously engage tumor antigens and T cell activating receptors (CD3, CD28 or others) — creating synthetic immunological synapses that redirect cytotoxic T cells to kill cancer cells. Third Arc's differentiation is in the multi-functionality of the format: rather than simple bispecific CD3 engagers (which cause severe cytokine release syndrome), Third Arc incorporates co-stimulatory and checkpoint-modulatory domains that tune T cell activation for safer, more durable anti-tumor responses.

### What tumor types does Third Arc Bio target?
Third Arc Bio focuses on solid tumor indications where conventional T cell engagers have struggled — pancreatic cancer, ovarian cancer, and lung cancer — due to the immunosuppressive tumor microenvironment that exhausts redirected T cells quickly. Third Arc's multifunctional format is designed to activate T cells and simultaneously counteract tumor immunosuppression, addressing the primary limitation of existing bispecific T cell engagers in solid tumors.

### Why did a16z invest specifically in Third Arc Bio's extension round?
a16z's entry as a new investor in Third Arc's extension funding reflects conviction in the solid tumor T cell engager thesis and validation of Third Arc's differentiated multifunctional antibody format. a16z Bio has been active in the engineered antibody space (also backing BioAtla, Seer Bio, and others), and Third Arc fits its thesis of companies using protein engineering advances to make previously intractable cancer targets druggable. New investor participation in an extension round signals positive scientific progress.

### What is the clinical development timeline for Third Arc Bio?
Third Arc Bio is in preclinical development, generating IND-enabling data on its lead multifunctional T cell engager programs in solid tumor models. The company's preclinical data package includes in vitro tumor cell killing assays, ex vivo human tumor explant studies, and in vivo xenograft and syngeneic tumor models demonstrating efficacy and safety signal versus conventional CD3 bispecifics. IND filing and Phase 1 study initiation are targeted for 2025-2026.

## Tags

healthtech, b2b

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*